SCHOTT Pharma is committed to responsible and good corporate governance. The goal of creating sustainable value for the company and its stakeholders is pursued in line with high international standards. For us, close coordination of the relevant bodies, a long-term corporate strategy, sound financial management and high transparency standards are essential pillars.
SCHOTT Pharma AG & Co. KGaA is led by its Management Board as well as an extended top management. The former acts as SCHOTT Pharma Management AG, which represents the General Partner in SCHOTT Pharma’s KGaA structure. The actions and decisions of the General Partner are aligned with the interests of the company. The management is responsible for the overall strategy, corporate planning, and business organisation.
Andreas Reisse is CEO of SCHOTT Pharma and has been responsible for this former SCHOTT business unit since 2010. Under his leadership, the company has developed into a leading provider of drug containment solutions and delivery systems, significantly increasing sales and profits in recent years. Previously, the industrial engineer headed the Tubing business unit, which manufactures pharmaceutical glass tubing - the essential starting material for SCHOTT Pharma's syringes, cartridges, vials and ampoules. During his time at Tubing, Andreas Reisse was also Head of Production in Spain for several years. Overall, he can build on more than 30 years of experience in the pharmaceutical industry. Prior to that, he worked as Head of Procurement for Volkswagen AG.
Dr. Almuth Steinkühler joined SCHOTT Pharma at the beginning of 2022. As CFO, she leads the commercial part of the company. In 13 years of experience in previous management roles, she held various finance positions at large German industrial companies. At Thyssenkrupp, she was responsible for Controlling, Accounting and Risk for the Chemical and Process Technologies business unit. In addition, she was an instrumental part in the carve-out for the preparation of a sale of a business unit. She also worked for Continental’s Oil & Marine business in the UK for several years.
Remuneration system for the members of the Management Board of the general partner
The Annual General Meeting of SCHOTT Pharma AG & Co. KGaA on 14 March 2024 approved the remuneration system for the members of the Management Board of the General Partner with a majority of 94.57 percent. The remuneration system for the members of the Management Board of the general partner can be found below.
The remuneration report can be found here: Compliance & statutes – SCHOTT Pharma (schott-pharma.com)
Supervisory Board
SCHOTT Pharma AG & Co. KGaA
The Supervisory Board of SCHOTT Pharma AG & Co. KGaA advises and monitors the Management Board and is involved in the decision-making processes on all important corporate topics.
The Supervisory Board consists of six members, including four shareholder representatives elected by the company’s Annual General Meeting (AGM) and two employee representatives.
The following CVs of members of the Supervisory Board are regularly updated. Changes will be published here as soon as they become known or following the publication of the latest AGM agenda. (Last update: April 2023)
Chairman
| Representative of | Shareholders |
|---|---|
| Member since | 4 April 2023 |
| Appointed until | Annual General Meeting for the fiscal year ending 30 September 2026 |
| Profession | Chairman of the Executive Board, CEO, Stada AG |
| Further supervisory board positions | - |
| CV | Peter Goldschmidt |
| Nationality | German |
Vice Chairman
| Representative of | Shareholders |
|---|---|
| Member since | 4 April 2023 |
| Appointed until | Annual General Meeting for the fiscal year ending 30 September 2026 |
| Profession | Chief Executive Officer, Siegfried AG |
| Further supervisory board positions | - |
| CV | Dr. Wolfgang Wienand |
| Nationality | German |
| Representative of | Shareholders |
|---|---|
| Member since | 4 April 2023 |
| Appointed until | Annual General Meeting for the fiscal year ending 30 September 2026 |
| Profession | Chief Financial Officer and member of the Management Board, KWS Saat SE & Co. KGaA |
| Further supervisory board positions | - Zumtobel Group, Dornbirn, Austria (Member of the Supervisory Board and Chairwoman of the Audit Committee) |
| CV | Eva Kienle |
| Nationality | German |
| Representative of | Shareholders |
|---|---|
| Member since | 4 April 2023 |
| Appointed until | Annual General Meeting for the fiscal year ending 30 September 2026 |
| Profession | Chief Financial Officer, SIG Group AG |
| Further supervisory board positions | - |
| CV | Ann-Kristin Erkens |
| Nationality | German |
| Representative of | Employees |
|---|---|
| Member since | 28 April 2023 |
| Appointed until | Annual General Meeting for the fiscal year ending 30 September 2026 |
| Profession | Head of Global Supply Chain Management, SCHOTT Pharma |
| Further supervisory board positions | - |
| CV | Christine Wening |
| Nationality | German |
| Representative of | Employees |
|---|---|
| Member since | 28 April 2023 |
| Appointed until | Annual General Meeting for the fiscal year ending 30 September 2026 |
| Profession | Chairman of the Works Council, Schott Pharma AG & Co. KGaA in Müllheim |
| Further supervisory board positions | - |
| CV | Mario Just |
| Nationality | German |
Remuneration system for the members of the Supervisory Board
The Annual General Meeting of SCHOTT Pharma AG & Co. KGaA on 14 March 2024 confirmed the remuneration of the members of the Supervisory Board, which is regulated in Section 13 of the Articles of Association, with a majority of 95.99 percent and approved the remuneration system for the members of the Supervisory Board. The remuneration system for the members of the Supervisory Board can be found below.
The remuneration report can be found here: Compliance & statutes – SCHOTT Pharma (schott-pharma.com)
In order to perform its duties effectively, the Supervisory Board of SCHOTT Pharma AG & Co. KGaA forms qualified committees, which prepare the topics of discussion and resolutions of the Supervisory Board. The Supervisory Board is informed regularly and promptly about the work of the committees.